A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of BIA 5 1058 in Healthy Volunteers
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Zamicastat (Primary)
- Indications Heart failure; Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors BIAL - Portela C S.A.
- 12 May 2020 Status changed from recruiting to completed.
- 25 Oct 2018 New trial record